Developer docs
API playgroundTry for free, no card

Search company profiles

GeneDx (Old)

Full company profile

uuid000a6ze

Namestring
GeneDx (Old)
Legal namestring
GeneDx, LLC
Websiteurl
genedx.com
Company typeenum
Private
Founded yearint
2000
Descriptiontext

GeneDx is a privately-held genetic testing company founded in 2000, operating as GeneDx, LLC with headquarters in Stamford, CT and a laboratory facility in Gaithersburg, MD. The company specializes in rare disease diagnosis through whole exome sequencing (ExomeDx) and whole genome sequencing (GenomeDx), with rapid turnaround variants including the GenomeDx ultraRapid platform for NICU/PICU critical care and GenomeDx Prenatal for fetal anomaly detection. GeneDx serves four primary customer segments: healthcare providers (75,000+ clinicians across pediatric neurology, general pediatrics, genetic counseling, and maternal-fetal medicine), patients and families, health systems (via Epic Aura EHR integration), and biopharma companies seeking data and research partnerships. The company is recognized as the #1 genetic test brand among pediatric and genetic specialists and is named one of Fast Company's Most Innovative Companies of 2025.

The company's competitive position is anchored by GeneDx Infinity, one of the world's largest rare disease genomic datasets containing 2.5+ million genetic tests, nearly 1 million exomes and genomes, 8+ million phenotypic data points, and 1.4+ billion clinical datapoints. AI-driven variant interpretation is enabled through MIMI Ranker, a proprietary tool that ranks 98% of diagnostic variants in the top 3 candidates across 16,000+ validation cases. Revenue is generated primarily through fee-for-service genetic testing billed to commercial insurance, Medicaid (36 states), Medicare, and TRICARE, supplemented by biopharma data partnership revenue. The company is in-network for 79% of commercially insured patients and reported Q3 2025 revenue of $116.7 million with 52% year-over-year growth and $14.7 million in net income.

Short descriptiontext

GeneDx is a privately-held genetic testing company providing whole exome and whole genome sequencing for rare disease diagnosis, serving 75,000+ clinicians, patients and families, health systems, and biopharma partners. The company leverages its proprietary GeneDx Infinity dataset of 2.5M+ tests and MIMI Ranker AI tool to deliver AI-augmented genomic interpretation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersStamford, United States
HQ citystring
Stamford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genetic testing services, whole genome sequencing, rare disease diagnostics, clinical genomic testing, exome sequencing
Industry1 code
PRIMARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Clinical Genetic Testing Services
Social media profiles3 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Genetic Testing Services
TypeOne Time License
Description

GeneDx generates revenue primarily through billing for genetic testing services (whole exome, whole genome, trio, targeted panels, prenatal). Tests are billed to commercial insurance, Medicaid, Medicare, and TRICARE. Self-pay options, interest-free payment plans, and financial assistance programs are also available. The company is an in-network provider for 79% of commercially insured patients.

genedx.com
2Biopharma Data and Research Services
TypeData Monetisation
Description

GeneDx partners with biopharma companies to leverage GeneDx Infinity™ data for target identification, natural history studies, clinical trial design, patient identification, health economics and outcomes research. Revenue is derived from data partnerships, research collaborations, and potentially licensing of genomic insights.

genedx.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Pricing details3 tiers
1Provider/telehealth intake service fee
ModelOne time/ perpetual licenseBilling cadenceOne time/ perpetual license
Notes

$39 upfront covers provider review, test selection, ordering (if appropriate), and delivering results. HSA and FSA accepted.

genedx.com
2Genome Medical genetic counseling (self-pay)
ModelFreemiumBilling cadencePay-as-you-go
Notes

Pre-test counseling, order placement, and results summary: $250. Post-test counseling (if desired): $250. Genome Medical is in network with many commercial insurers.

genedx.com
3Insurance-covered testing
ModelSubscriptionBilling cadenceMonthly
Notes

GeneDx accepts all commercial insurance, Medicaid, Medicare, and TRICARE. Final cost depends on plan copay, coinsurance, and deductible. If estimated out-of-pocket exceeds $250, patients are notified before testing proceeds.

genedx.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1GeneDx Infinity
Description

One of the most powerful tools for accelerating diagnoses and fueling drug discovery. Draws on 2.5+ million genetic tests, nearly 1 million exomes and genomes, and 8 million phenotypic data points.

genedx.com
+5 more records
Core offering1 text field

GeneDx is a clinical genomics company that performs whole exome sequencing (ExomeDx) and whole genome sequencing (GenomeDx), including rapid and ultraRapid tests for NICU/PICU patients, prenatal tests (GenomeDx Prenatal), trio testing, and targeted panels, to diagnose rare and inherited diseases. It also operates GeneDx Infinity, one of the world's largest rare disease genomic datasets (2.5M+ tests, ~1M exomes/genomes, 8M+ phenotypic data points), which it monetizes through biopharma data and research partnerships. AI-powered variant prioritization is delivered via MIMI Ranker.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • Diagnostic yield 17% greater than standard testing
+7 more records
Product overview1 text field

GeneDx is a genetic testing company offering a comprehensive portfolio of genomic diagnostics centered on whole exome sequencing (ExomeDx) and whole genome sequencing (GenomeDx) products. The core testing suite includes standard and rapid turnaround options (GenomeDx ultraRapid) for critically ill patients, prenatal testing (GenomeDx Prenatal), and trio testing that incorporates parental samples for improved diagnostic yield. The company operates GeneDx Infinity, a proprietary data platform containing one of the world's largest rare disease genomic datasets. AI-powered variant interpretation is enabled through MIMI Ranker. GeneDx serves providers, patients and families, health systems, and biopharma partners across pediatric neurology, general pediatrics, genetic counseling, and maternal-fetal medicine specialties.

Product and service8 records
1ExomeDx (Whole Exome Sequencing)
CategoryClinical Genetic Testing
Description

Whole exome sequencing test that analyzes the protein-coding portions of approximately 20,000 genes to identify genetic causes of rare and inherited conditions, offering higher diagnostic yield than chromosomal microarray or targeted gene panels. Sold to healthcare providers and accessed by patients via provider order or telehealth partnership.

2GenomeDx (Whole Genome Sequencing)
CategoryClinical Genetic Testing
Description

Whole genome sequencing test providing comprehensive analysis of a patient's entire genome including non-coding regions, enabling the greatest chance of identifying the genetic changes responsible for rare and complex conditions. Ordered by healthcare providers; supported by GeneDx provider portal and at-home sample collection.

3GenomeDx Prenatal
CategoryClinical Genetic Testing
Description

Trio-based whole genome sequencing diagnostic test specifically designed for fetal anomalies detected during pregnancy, providing genomic insights with less than two-week turnaround time. Covers prenatal indications including congenital heart disease, skeletal dysplasia, and brain and kidney malformations.

4GenomeDx ultraRapid (proband, duo, trio)
CategoryClinical Genetic Testing
Description

Rapid whole genome sequencing for critically ill infants in NICU/PICU settings, delivering results in as soon as 48 hours. Available in proband, duo (patient plus one parent), and trio (patient plus both parents) configurations to accelerate diagnostic certainty.

5Trio Testing
CategoryClinical Genetic Testing
Description

Genetic testing approach that analyzes DNA from the patient plus both biological parents to improve diagnostic yield and reduce inconclusive findings, distinguishing de novo from inherited variants and enabling more confident clinical decisions.

6GeneDx Infinity
CategoryGenomic Data Platform
Description

One of the world's largest rare disease genomic datasets combining 2.5M+ genetic tests, nearly 1M exomes and genomes, and 8M+ phenotypic data points. Connected with Komodo Health real-world evidence data to support biopharma in target identification, natural history studies, clinical trial design, patient identification, and health economics and outcomes research.

7Prenatal Genetic Testing
CategoryClinical Genetic Testing
Description

Comprehensive prenatal genetic testing services including amniotic fluid collection and analysis for detecting fetal genetic conditions during pregnancy, available to maternal-fetal medicine specialists.

8Targeted Variant Testing
CategoryClinical Genetic Testing
Description

Focused genetic testing for specific known variants or targeted gene panels when the genetic cause is suspected to lie within particular genes, available to providers and patients.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-15
Description

Illumina partnered with GeneDx to pilot its Constellation Mapped Read Technology, designed to uncover challenging genomic insights. The pilot study evaluated the technology's performance on challenging genomic regions using 160 samples. The technology is scheduled for release in the first half of 2026 and aims to enhance DNA sequencing applications in research and clinical markets.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

GeneDx partners with Komodo Health to connect genomic and phenotypic data from GeneDx Infinity™ with longitudinal real-world claims data, creating one of the most comprehensive rare disease datasets in healthcare. This partnership supports biopharma in target identification, natural history studies, clinical trial design, patient identification, and health economics and outcomes research.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Genome Medical provides telehealth genetic counseling and test ordering services for GeneDx, enabling patients to virtually meet with board-certified genetic counselors and start the testing process from the comfort of their home. Genome Medical's clinical team includes experienced genetic counselors, medical geneticists, and specialists who provide care across all 50 states.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

DNAvisit is a network of medical providers partnered with GeneDx to support patients seeking genetic testing for developmental delays. DNAvisit providers review patient intake, select appropriate tests, place orders, and discuss results with families through virtual visits.

Strategic tierCoreTypeTechnology or Integration
Description

GeneDx offers Epic Aura EHR integration for health systems, enabling seamless ordering and result delivery within the Epic electronic health record system to support precision medicine across hospital networks.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Market position
Competitive moat7 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GeneDx (Old)

Clinical Genetic Testing Servicesgenedx.com

GeneDx is a privately-held genetic testing company providing whole exome and whole genome sequencing for rare disease diagnosis, serving 75,000+ clinicians, patients and families, health systems, and biopharma partners. The company leverages its proprietary GeneDx Infinity dataset of 2.5M+ tests and MIMI Ranker AI tool to deliver AI-augmented genomic interpretation.

What GeneDx (Old) does

GeneDx is a privately-held genetic testing company founded in 2000, operating as GeneDx, LLC with headquarters in Stamford, CT and a laboratory facility in Gaithersburg, MD. The company specializes in rare disease diagnosis through whole exome sequencing (ExomeDx) and whole genome sequencing (GenomeDx), with rapid turnaround variants including the GenomeDx ultraRapid platform for NICU/PICU critical care and GenomeDx Prenatal for fetal anomaly detection. GeneDx serves four primary customer segments: healthcare providers (75,000+ clinicians across pediatric neurology, general pediatrics, genetic counseling, and maternal-fetal medicine), patients and families, health systems (via Epic Aura EHR integration), and biopharma companies seeking data and research partnerships. The company is recognized as the #1 genetic test brand among pediatric and genetic specialists and is named one of Fast Company's Most Innovative Companies of 2025.

The company's competitive position is anchored by GeneDx Infinity, one of the world's largest rare disease genomic datasets containing 2.5+ million genetic tests, nearly 1 million exomes and genomes, 8+ million phenotypic data points, and 1.4+ billion clinical datapoints. AI-driven variant interpretation is enabled through MIMI Ranker, a proprietary tool that ranks 98% of diagnostic variants in the top 3 candidates across 16,000+ validation cases. Revenue is generated primarily through fee-for-service genetic testing billed to commercial insurance, Medicaid (36 states), Medicare, and TRICARE, supplemented by biopharma data partnership revenue. The company is in-network for 79% of commercially insured patients and reported Q3 2025 revenue of $116.7 million with 52% year-over-year growth and $14.7 million in net income.

GeneDx (Old) firmographics

Firmographics
Name
GeneDx (Old)
Legal name
GeneDx, LLC
Website
https://genedx.com
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
GeneDx is a privately-held genetic testing company providing whole exome and whole genome sequencing for rare disease diagnosis, serving 75,000+ clinicians, patients and families, health systems, and biopharma partners. The company leverages its proprietary GeneDx Infinity dataset of 2.5M+ tests and MIMI Ranker AI tool to deliver AI-augmented genomic interpretation.
Ownership category
akta.pro rank

GeneDx (Old) industry classification

Industry
Product category
Clinical Genetic Testing Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)

Keywords

  • Genetic testing services
  • Whole genome sequencing
  • Rare disease diagnostics
  • Clinical genomic testing
  • Exome sequencing

Where GeneDx (Old) is headquartered

Location

Headquarters

HQ city
Stamford
HQ country
United States
HQ region
North America

Offices2 records

Markets served

GeneDx (Old) business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Genetic Testing Services: GeneDx generates revenue primarily through billing for genetic testing services (whole exome, whole genome, trio, targeted panels, prenatal). Tests are billed to commercial insurance, Medicaid, Medicare, and TRICARE. Self-pay options, interest-free payment plans, and financial assistance programs are also available. The company is an in-network provider for 79% of commercially insured patients.
  2. Biopharma Data and Research Services: GeneDx partners with biopharma companies to leverage GeneDx Infinity™ data for target identification, natural history studies, clinical trial design, patient identification, health economics and outcomes research. Revenue is derived from data partnerships, research collaborations, and potentially licensing of genomic insights.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseOne time/ perpetual licenseProvider/telehealth intake service fee
FreemiumPay-as-you-goGenome Medical genetic counseling (self-pay)
SubscriptionMonthlyInsurance-covered testing

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

GeneDx (Old) product offering

Product offering

Core offering

GeneDx is a clinical genomics company that performs whole exome sequencing (ExomeDx) and whole genome sequencing (GenomeDx), including rapid and ultraRapid tests for NICU/PICU patients, prenatal tests (GenomeDx Prenatal), trio testing, and targeted panels, to diagnose rare and inherited diseases. It also operates GeneDx Infinity, one of the world's largest rare disease genomic datasets (2.5M+ tests, ~1M exomes/genomes, 8M+ phenotypic data points), which it monetizes through biopharma data and research partnerships. AI-powered variant prioritization is delivered via MIMI Ranker.

Product overview

GeneDx is a genetic testing company offering a comprehensive portfolio of genomic diagnostics centered on whole exome sequencing (ExomeDx) and whole genome sequencing (GenomeDx) products. The core testing suite includes standard and rapid turnaround options (GenomeDx ultraRapid) for critically ill patients, prenatal testing (GenomeDx Prenatal), and trio testing that incorporates parental samples for improved diagnostic yield. The company operates GeneDx Infinity, a proprietary data platform containing one of the world's largest rare disease genomic datasets. AI-powered variant interpretation is enabled through MIMI Ranker. GeneDx serves providers, patients and families, health systems, and biopharma partners across pediatric neurology, general pediatrics, genetic counseling, and maternal-fetal medicine specialties.

Differentiator

Problem solved

Functional benefit

Brands

  • GeneDx Infinity: One of the most powerful tools for accelerating diagnoses and fueling drug discovery. Draws on 2.5+ million genetic tests, nearly 1 million exomes and genomes, and 8 million phenotypic data points.
  • GenomeDx
  • ExomeDx
  • MIMI Ranker
  • DNAvisit
  • Genome Medical

Products and services

  • ExomeDx (Whole Exome Sequencing) Whole exome sequencing test that analyzes the protein-coding portions of approximately 20,000 genes to identify genetic causes of rare and inherited conditions, offering higher diagnostic yield than chromosomal microarray or targeted gene panels. Sold to healthcare providers and accessed by patients via provider order or telehealth partnership.
  • GenomeDx (Whole Genome Sequencing) Whole genome sequencing test providing comprehensive analysis of a patient's entire genome including non-coding regions, enabling the greatest chance of identifying the genetic changes responsible for rare and complex conditions. Ordered by healthcare providers; supported by GeneDx provider portal and at-home sample collection.
  • GenomeDx Prenatal Trio-based whole genome sequencing diagnostic test specifically designed for fetal anomalies detected during pregnancy, providing genomic insights with less than two-week turnaround time. Covers prenatal indications including congenital heart disease, skeletal dysplasia, and brain and kidney malformations.
  • GenomeDx ultraRapid (proband, duo, trio) Rapid whole genome sequencing for critically ill infants in NICU/PICU settings, delivering results in as soon as 48 hours. Available in proband, duo (patient plus one parent), and trio (patient plus both parents) configurations to accelerate diagnostic certainty.
  • Trio Testing Genetic testing approach that analyzes DNA from the patient plus both biological parents to improve diagnostic yield and reduce inconclusive findings, distinguishing de novo from inherited variants and enabling more confident clinical decisions.
  • GeneDx Infinity One of the world's largest rare disease genomic datasets combining 2.5M+ genetic tests, nearly 1M exomes and genomes, and 8M+ phenotypic data points. Connected with Komodo Health real-world evidence data to support biopharma in target identification, natural history studies, clinical trial design, patient identification, and health economics and outcomes research.
  • Prenatal Genetic Testing Comprehensive prenatal genetic testing services including amniotic fluid collection and analysis for detecting fetal genetic conditions during pregnancy, available to maternal-fetal medicine specialists.
  • Targeted Variant Testing Focused genetic testing for specific known variants or targeted gene panels when the genetic cause is suspected to lie within particular genes, available to providers and patients.

Quantifiable outcome

  • Diagnostic yield 17% greater than standard testing
  • +7 more outcomes

Companies that use GeneDx (Old)

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles4 records

GeneDx (Old) technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability5 records

Feature4 records

GeneDx (Old) partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • IlluminacoreTechnology or Integration · 15 October 2025Illumina partnered with GeneDx to pilot its Constellation Mapped Read Technology, designed to uncover challenging genomic insights. The pilot study evaluated the technology's performance on challenging genomic regions using 160 samples. The technology is scheduled for release in the first half of 2026 and aims to enhance DNA sequencing applications in research and clinical markets.
  • Komodo HealthcoreStrategic or Co-development PartnerGeneDx partners with Komodo Health to connect genomic and phenotypic data from GeneDx Infinity™ with longitudinal real-world claims data, creating one of the most comprehensive rare disease datasets in healthcare. This partnership supports biopharma in target identification, natural history studies, clinical trial design, patient identification, and health economics and outcomes research.
  • Genome MedicalcoreChannel Partner/ Reseller/ DistributorGenome Medical provides telehealth genetic counseling and test ordering services for GeneDx, enabling patients to virtually meet with board-certified genetic counselors and start the testing process from the comfort of their home. Genome Medical's clinical team includes experienced genetic counselors, medical geneticists, and specialists who provide care across all 50 states.
  • DNAvisitminorChannel Partner/ Reseller/ DistributorDNAvisit is a network of medical providers partnered with GeneDx to support patients seeking genetic testing for developmental delays. DNAvisit providers review patient intake, select appropriate tests, place orders, and discuss results with families through virtual visits.
  • Epic (Epic Aura)coreTechnology or IntegrationGeneDx offers Epic Aura EHR integration for health systems, enabling seamless ordering and result delivery within the Epic electronic health record system to support precision medicine across hospital networks.

Scale indicators10 records

Recent moves6 records

Expansion highlights8 records

GeneDx (Old) competitors and assessment

Company assessment

Market position

Competitive moat7 records

Key highlights7 records

Customer concentration

GeneDx (Old) social profiles

Digital presence

GeneDx (Old) compliance and trust

Trust signal

Compliance1 record

GeneDx (Old) financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GeneDx (Old) leadership team

Management profile

Number of profiles

Profiles3 records

GeneDx (Old) funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GeneDx (Old) M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GeneDx (Old)

What does GeneDx (Old) do?

GeneDx is a clinical genomics company that performs whole exome sequencing (ExomeDx) and whole genome sequencing (GenomeDx), including rapid and ultraRapid tests for NICU/PICU patients, prenatal tests (GenomeDx Prenatal), trio testing, and targeted panels, to diagnose rare and inherited diseases. It also operates GeneDx Infinity, one of the world's largest rare disease genomic datasets (2.5M+ tests, ~1M exomes/genomes, 8M+ phenotypic data points), which it monetizes through biopharma data and research partnerships. AI-powered variant prioritization is delivered via MIMI Ranker.

Is GeneDx (Old) a public or private company?

GeneDx (Old) is a private company. It is classified as unknown and is currently operating.

When was GeneDx (Old) founded?

GeneDx (Old) was founded in 2000. It employs 1,001 to 5,000 people.

Where is GeneDx (Old) based?

GeneDx (Old) is headquartered in Stamford, United States, in the North America region.

How does GeneDx (Old) make money?

Two revenue lines are on record. Genetic Testing Services are the primary driver. The others are biopharma Data and Research Services.

Does GeneDx (Old) have an API?

No public API is recorded for GeneDx (Old).

What industry is GeneDx (Old) in?

GeneDx (Old)'s product category is Clinical Genetic Testing Services. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketWatchGeneDx Hires Quanterix's Everett Cunningham as New CEOGeneDx hired Everett Cunningham as CEO, effective Dec. 15, succeeding Katherine Stueland. He will earn a $750,000 base salary and $1.05 million sign-on bonus. Quanterix, where he left, appointed Jim Gute as interim CEO.Investing.comGeneDx names Everett Cunningham as new chief executiveGeneDx appointed Everett Cunningham as CEO, effective on or before December 15, 2026, succeeding Katherine Stueland, who will remain in an advisory capacity through January 31, 2027. Cunningham brings over 35 years of experience in diagnostics and genomics, including roles at Illumina, Exact Sciences, and Pfizer. The company reaffirmed its full-year 2026 financial guidance.Seeking AlphaGeneDx names new CEOGeneDx appointed Everett Cunningham as CEO and board member, effective on or before December 15, 2026. He will succeed Katherine Stueland, who has announced her departure. The company's stock closed at $47.29, down 7.31%.TradingViewGeneDx names new CEOGeneDx appointed Everett Cunningham as CEO and board member, effective on or before December 15, 2026. He succeeds Katherine Stueland, who will remain in an advisory capacity through January 31, 2027. Cunningham comes from Quanterix Corporation, where he was president and CEO.Business Wire BlogGeneDx Announces Leadership TransitionGeneDx appointed Everett Cunningham as CEO, effective on or before December 15, 2026, succeeding Katherine Stueland, who will remain in an advisory capacity through January 31, 2027. Cunningham brings over 35 years of experience from Quanterix and other diagnostics firms. The company reaffirmed its full-year 2026 financial guidance.Stock TitanGeneDx appoints Everett Cunningham CEO, effective by Dec. 15GeneDx appointed Everett Cunningham as CEO, effective on or before December 15, 2026, succeeding Katherine Stueland, who will remain in an advisory capacity through January 31, 2027. Cunningham brings over 35 years of experience from Quanterix, Illumina, and other diagnostics firms. The company reaffirmed its full-year 2026 financial guidance.Investing.comGeneDx at Jefferies Global Healthcare Conference: focus on collectionsGeneDx outlined its revenue cycle management overhaul at the Jefferies Global Healthcare Conference, targeting 30% annual volume growth. The company reported Q3 volume growth of 25% and a genome collection rate improvement from 32% to 36%, with current rates around 30-40% versus a long-term target of 70-80%. It expects automated workflows and AI tools to go live in Q4 and Q1.Simply Wall StGeneDx Holdings (WGS) Research And Mirum Deal Lead Focus, Is It A Bargain?GeneDx Holdings' exome and genome sequencing informed clinical management in over 60% of tested patients, and it partnered with Mirum Pharmaceuticals for no-cost rare disease testing. The stock trades at $52.37, down 60.42% year-to-date, with a fair value estimate of $93.50. Payer reimbursement and outpatient collection rates remain key risks.The future of tradingGeneDx to Participate in Jefferies and Piper Sandler Healthcare ConferencesGeneDx management will attend the 2026 Jefferies Global Healthcare Conference in London on Nov. 17 for a 4:30 p.m. GMT fireside chat, and a Piper Sandler 38th Annual Healthcare Conference in New York on Dec. 2 at 9 a.m. ET.Business Wire BlogGeneDx to Participate in Upcoming Investor ConferencesGeneDx management will participate in the 2026 Jefferies Global Healthcare Conference in London on November 17 and the Piper Sandler 38th Annual Healthcare Conference in New York on December 2. Live and archived webcasts will be available on the company's investor relations website.